FOLD Q3 2024 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$142M+36.7% YoY

Gross Profit

$128M90.6% margin

Operating Income

$22M15.3% margin

Net Income

-$7M-4.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$787M

Total Liabilities

$608M

Stockholders' Equity

$179M

Cash & Equivalents

$234M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$142M	$104M	+36.7%
Gross Profit	$128M	$94M	+37.1%
Operating Income	$22M	-$17M	+227.2%
Net Income	-$7M	-$22M	+68.8%

Geographic Segments

Non-US

$85M60%

UNITED STATES

$56M40%